نتایج جستجو برای: phenformin

تعداد نتایج: 275  

Journal: :The EMBO journal 2005
Kei Sakamoto Afshan McCarthy Darrin Smith Kevin A Green D Grahame Hardie Alan Ashworth Dario R Alessi

Recent studies indicate that the LKB1 tumour suppressor protein kinase is the major "upstream" activator of the energy sensor AMP-activated protein kinase (AMPK). We have used mice in which LKB1 is expressed at only approximately 10% of the normal levels in muscle and most other tissues, or that lack LKB1 entirely in skeletal muscle. Muscle expressing only 10% of the normal level of LKB1 had si...

2018
Amy R. Cameron Lisa Logie Kashyap Patel Stefan Erhardt Sandra Bacon Paul Middleton Jean Harthill Calum Forteath Josh T. Coats Calum Kerr Heather Curry Derek Stewart Kei Sakamoto Peter Repiščák Martin J. Paterson Ilmo Hassinen Gordon McDougall Graham Rena

Many guanide-containing drugs are antihyperglycaemic but most exhibit toxicity, to the extent that only the biguanide metformin has enjoyed sustained clinical use. Here, we have isolated unique mitochondrial redox control properties of metformin that are likely to account for this difference. In primary hepatocytes and H4IIE hepatoma cells we found that antihyperglycaemic diguanides DG5-DG10 an...

Journal: :Thrombosis et diathesis haemorrhagica 1975
U Hedner I M Nilsson S Isacson

Forty-nine patients with decreased fibrinolytic activity in the vessel walls or a decreased release mechanism, or both, were treated with ethyloestrenol for three to 17 months. Forty-five of the patients had had recurrent, phlebographically verified, deep venous thrombosis (DVT) and four had arterial thrombosis. Ethyloestrenol 8 mg/day was given to 31 patients and 4 mg/day was given to 12. The ...

2013
Ping Yuan Koichi Ito Rolando Perez-Lorenzo Christina Del Guzzo Jung Hyun Lee Che-Hung Shen Marcus W. Bosenberg Martin McMahon Lewis C. Cantley Bin Zheng

Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129; Institute for Cancer Genetics and Departments of Dermatology and Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032; Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520; Helen Diller Family Comprehensive Cancer Center...

Journal: :Cancer prevention research 2015
Zongjian Zhu Weiqin Jiang Matthew D Thompson Dimas Echeverria John N McGinley Henry J Thompson

Metformin is a widely prescribed drug for the treatment of type II diabetes. Although epidemiologic data have provided a strong rationale for investigating the potential of this biguanide for use in cancer prevention and control, uncertainty exists whether metformin should be expected to have an impact in nondiabetic patients. Furthermore, little attention has been given to the possibility that...

Journal: :Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 2004
Zhouping Wang Zhujun Zhang Zhifeng Fu Luqiu Fang Xiao Zhang

A novel and highly sensitive method for the determination of phenformin over the range of 6 x 10(-9) - 1 x 10(-5) g ml(-1) in pharmaceutical formulations with flow-injection chemiluminescence (CL) detection is proposed. The method is based on the CL produced during the oxidation of N-bromosuccinimide (NBS) in an alkaline medium in the presence of fluorescein as an effective energy transfer agen...

Journal: :Postgraduate medical journal 1968
H Keen R J Jarrett

IN 1918, Watanabe first demonstrated the hypoglycaemic properties of guanidine. After nearly 40 years of sporadic investigation of its derivatives, including the misadventures with synthalin (Frank, Nothmann & Wagner, 1926), this observation bore clinical fruit in the first of the biguanides, phenylethylbiguanide (phenformin) see Fig. 1). Other biguanides have since appeared including dimethylb...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید